Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
Kissling E., Hooiveld M., Sandonis Martín V., Martínez-Baz I., William N., Vilcu AM., Mazagatos C., Domegan L., de Lusignan S., Meijer A., Machado A., Brytting M., Casado I., Murray JLK., Belhillil S., Larrauri A., O'Donnell J., Tsang R., de Lange M., Rodrigues AP., Riess M., Castilla J., Hamilton M., Falchi A., Pozo F., Dunford L., Cogdale J., Jansen T., Guiomar R., Enkirch T., Burgui C., Sigerson D., Blanchon T., Martínez Ochoa EM., Connell J., Ellis J., van Gageldonk-Lafeber R., Kislaya I., Rose AM., Valenciano M.
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.